Synta Pharmaceuticals (SNTA) 4.26 $SNTA
5 Stocks Under $10 Set to Soar
at The Street - Thu May 08, 12:57PM CDT
These under-$10 stocks look poised to trade higher from current levels.
Rectal Cancer - Pipeline Review, H1 2014
M2 - Thu May 08, 6:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d94ppq/rectal_cancer) has announced the addition of the "Rectal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Rectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rectal Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Rectal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Rectal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Rectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Rectal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - AbbVie Inc. - Celltrion, Inc. - Eisai Co., Ltd. - GenVec, Inc. - GlaxoSmithKline plc - Hanwha Chemical Corporation - Isofol Medical AB - Merck & Co., Inc. - Merck KGaA - Nanobiotix - Peregrine Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. For more information visit http://www.researchandmarkets.com/research/d9...tal_cancer
Synta Reports First Quarter 2014 Financial Results and Provides Corporate Update
Business Wire - Thu May 08, 6:01AM CDT
--Ganetespib Included in Six Large, Randomized Clinical Trials
Synta Announces Results From Final Analysis of the GALAXY-1 Trial of Ganetespib in NSCLC
Business Wire - Thu May 08, 6:01AM CDT
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced final results from the GALAXY-1 trial, a global, randomized, multi-center study designed to identify the patients with advanced non-small cell lung cancer (NSCLC) with adenocarcinoma histology most likely to benefit from second-line treatment with the Company's lead drug candidate, the Hsp90 inhibitor ganetespib, in combination with docetaxel versus docetaxel alone. Ganetespib is a next-generation inhibitor of the chaperone protein Hsp90, which is critical for the activation and stability of numerous proteins that drive cancer growth and proliferation. Ganetespib has been studied in over 1000 patients to date.
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/grpwf5/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Involved: - ATLAB Pharma SAS - AbbVie Inc. - Active Biotech AB - Astellas Pharma Inc. - AstraZeneca PLC - Bavarian Nordic A/S - Bellicum Pharmaceuticals, Inc. - Bind Therapeutics, Inc. - Bostwick Laboratories, Inc. - CellCentric Ltd. - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - Exelixis, Inc. - GTx, Inc. - GenSpera, Inc. - Genentech, Inc. - Medivation, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Novartis AG - Oncolytics Biotech Inc. - Oncothyreon Inc. - Onyx Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Sotio a.s. - Supratek Pharma Inc. - Synta Pharmaceuticals Corp. Drug Profiles: - enzalutamide - orteronel - custirsen sodium - tasquinimod - enzalutamide - cabozantinib (s)-malate - Prostvac - DCVAC/PCa - patupilone - DI-17-E-6 - olaratumab - navitoclax - vandetanib - PSMA ADC - GTx-758 - linsitinib - olaparib - panobinostat - carfilzomib - ganetespib - pelareorep - PX-866 - CV-9103 - G-202 - docetaxel targeted nanoparticles - buparlisib hydrochloride - NLG-8189 - Adenovirus/PSA Vaccine - TL-118 - CV-9104 For more information visit http://www.researchandmarkets.com/research/grpwf5/metastatic
Fallopian Tube Cancer - Pipeline Review, H1 2014: 30 Companies and 37 Drugs Profiled
M2 - Wed May 07, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7chq8b/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Amgen Inc. - Boehringer Ingelheim GmbH - California Stem Cell, Inc. - Cell Therapeutics, Inc. - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Daiichi Sankyo Company, Limited - EGEN, Inc. - Eli Lilly and Company - GlaxoSmithKline plc - ImmunoGen, Inc. - Immunovaccine, Inc. - Incyte Corporation - Lee's Pharmaceutical Holdings Limited - MEI Pharma, Inc. - MabVax Therapeutics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OncoMed Pharmaceuticals, Inc. - Oncolytics Biotech Inc. - Oxford BioMedica plc - Pharma Mar, S.A. - Pharmacyclics, Inc. - Recepta Biopharma S.A. - Spectrum Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - TRION Pharma GmbH Drug Profiles: - pazopanib hydrochloride - trebananib - paclitaxel poliglumex - paclitaxel - MEK-162 - idronoxil - trabectedin - alisertib - dalantercept - elesclomol - TroVax - ramucirumab - pelareorep - nintedanib - catumaxomab - CRLX-101 - VTX-2337 - gimatecan - exatecan mesylate - RebmAb-100 - EGEN-001 - NSC-748933 - INCB-24360 - birinapant - rucaparib - metformin - Cancer Stem Cell Therapy - DPX-Survivac - ganetespib - pralatrexate For more information visit http://www.researchandmarkets.com/research/7c...opian_tube
Synta to Host Conference Call and Webcast of First Quarter 2014 Financial Results on May 8, 2013
Business Wire - Tue Apr 29, 4:00PM CDT
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that it will report its first quarter 2014 financial results on Thursday, May 8, 2014, before market open.
Global Gastrointestinal Stromal Tumor (GIST) Therapeutics Pipeline Review 2014 - Analysis of 16 Companies & 23 Drug Profiles
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8rx8bp/gastrointestinal) has announced the addition of the "Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumor (GIST) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Gastrointestinal Stromal Tumor (GIST) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Gastrointestinal Stromal Tumor (GIST) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Eli Lilly and Company - Novartis AG - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Bayer AG - Ariad Pharmaceuticals, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chipscreen Biosciences Ltd - Ambit Biosciences Corporation - Deciphera Pharmaceuticals, LLC - Xcovery, Inc. - AB Science - Clovis Oncology, Inc. - EirGen Pharma Ltd. - AROG Pharmaceuticals LLC Drug Profiles - regorafenib - masitinib - nilotinib - masitinib - olaratumab - linsitinib - ponatinib - AT-13387 - ganetespib - dovitinib lactate - crenolanib - luminespib - MEK-162 - TH-302 - buparlisib hydrochloride - CS-2164 - Mixed Bacterial Vaccine - X-82 - quizartinib - DCC-2618 - Mutant cKIT Inhibitor - Drug Targeting c-Kit - Eir-108 For more information visit http://www.researchandmarkets.com/research/8r...intestinal
Global Polycystic Kidney Disease Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8fdfv7/polycystic_kidney) has announced the addition of the "Global Polycystic Kidney Disease Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Polycystic Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Kidney Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Emergent BioSolutions Inc. - Plexxikon Inc. - Pfizer Inc. - Synta Pharmaceuticals Corp. - Metabolic Solutions Development Co. - IC-MedTech, Inc. - Endocyte, Inc. - ManRos Therapeutics - DiscoveryBiomed, Inc. - Otsuka Holdings Co., Ltd. - Kadmon Pharmaceuticals, LLC Drug Profiles - tolvaptan - tolvaptan - lanreotide acetate - bosutinib - KD-020 - KD-019 - GLG-302 - MSDC-0160 - MSDC-0602 - TNFR x TWEAKR - EC-0371 - Polycystic Kidney Disease Program - Small Molecule to Inhibit Raf Kinase for Polycystic Kidney Disease - STA-2842 - RCMC-30 - Small Moleucles to Activate AMPK for Polycystic Kidney Disease - Drug For Polycstic Kidney Disease - Drugs Targeting CIL-1 for Genetic Disorders and Polycystic Kidney Disease - Drugs for Polycystic Kidney Disease - Small Molecules to Activate Somatostatin Receptor Type 4 for Oncology, Genito Urinary System And Sex Hormones and Metabolic Disorders - (Vitamin C Vitamin K3) For more information visit http://www.researchandmarkets.com/research/8f...tic_kidney
Global Peritoneal Cancer Therapeutics Pipeline Review 2014 - Analysis of 32 Companies & 37 Drug Profiles
M2 - Tue Apr 22, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kk76kx/peritoneal_cancer) has announced the addition of the "Peritoneal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peritoneal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peritoneal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peritoneal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Peritoneal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Boehringer Ingelheim GmbH - AstraZeneca PLC - GlaxoSmithKline plc - Bioniche Life Sciences, Inc. - Daiichi Sankyo Company, Limited - Oxford BioMedica plc - Millennium Pharmaceuticals, Inc. - Novartis AG - ImmunoGen, Inc. - Bayer AG - Incyte Corporation - Oncolytics Biotech Inc. - Pharmacyclics, Inc. - Synta Pharmaceuticals Corp. - Oasmia Pharmaceutical AB - MabVax Therapeutics, Inc. - Spectrum Pharmaceuticals, Inc. - Acceleron Pharma, Inc. - TRION Pharma GmbH - CerRx, Inc. - OncoMed Pharmaceuticals, Inc. - TetraLogic Pharmaceuticals - Innate Therapeutics Limited - CritiTech, Inc. - Pharma Mar, S.A. - VentiRx Pharmaceuticals, Inc. - Genelux Corporation - Clovis Oncology, Inc. - California Stem Cell, Inc. - EGEN, Inc. Drug Profiles - Cancer Stem Cell Therapy - DPX-Survivac - EGEN-001 - GL-ONC-1 - Globo-H-GM2-sTn-TF-Tn-KLH Vaccine - IMGN-853 - IMT-1012 - INCB-24360 - MEK-162 - MIS-416 - MV-NIS Vaccine - Mycobacterial Cell Wall-DNA Complex Program - NSC-748933 - OC-DC Vaccine - Theranean - TroVax - VTX-2337 - abexinostat hydrochloride - alisertib - birinapant - catumaxomab - dalantercept - demcizumab - elesclomol - exatecan mesylate - fenretinide - ganetespib - metformin - nintedanib For more information visit http://www.researchandmarkets.com/research/kk...eal_cancer
Global Metastatic Pancreatic Cancer Therapeutics Pipeline Review 2014 - Analysis of 27 Companies & 37 Drug Profiles
M2 - Tue Apr 22, 3:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gctlqw/metastatic) has announced the addition of the "Metastatic Pancreatic Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Pancreatic Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Pancreatic Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Metastatic Pancreatic Cancer - Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Adherex Technologies Inc. - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - FibroGen, Inc. - Novartis AG - Pfizer Inc. - Celgene Corporation - Bayer AG - Halozyme Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - Immunomedics, Inc. - Synta Pharmaceuticals Corp. - NanoCarrier Co., Ltd. - Rexahn Pharmaceuticals, Inc. - Insys Therapeutics, Inc. - OncoMed Pharmaceuticals, Inc. - Merrimack Pharmaceuticals, Inc. - Pharma Mar, S.A. - AB Science - Oncovir, Inc. - ParinGenix, Inc. - Regulon Inc. - Fountain Biopharma Inc. - Oncozyme Pharma Inc. - AbbVie Inc. Drug Profiles - paclitaxel albumin-bound - irinotecan sucrosofate liposomal - masitinib - cisplatin liposomal - cisplatin - refametinib - selumetinib sulfate - trametinib dimethyl sulfoxide - docetaxel - paclitaxel albumin-bound - ganetespib - RX-0201 - irinotecan sucrosofate liposomal - PGX-100 - lurbinectedin - yttrium Y 90 clivatuzumab tetraxetan - Cancer Inhibitor Macrobeads - TL-118 - LY-2090314 - hydroxychloroquine - LY-2495655 - PEGPH-20 - M-402 - pentamidine isethionate - veliparib - galunisertib - ADH-1 - FG-3019 - demcizumab - LCL-161 For more information visit http://www.researchandmarkets.com/research/gctlqw/metastatic
5 Stocks Insiders Love Right Now
at The Street - Wed Apr 16, 12:06PM CDT
Insiders at these companies are scooping up shares of their own stock lately.
Synta Pharmaceuticals Enters Into Agreement to Sell $5.0 Million in Common Stock Directly to an Affiliate of Synta Board Member Bruce Kovner
Business Wire - Mon Apr 14, 7:02AM CDT
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the entry into a Subscription Agreement with an entity affiliated with Bruce Kovner, one of Synta's directors and its largest stockholder, to sell 1,250,000 shares of its common stock at a price of $4.01 per share. The proceeds to Synta are expected to be approximately $5.0 million after deducting estimated offering expenses payable by Synta. The shares were offered directly without a placement agent, underwriter, broker or dealer.
Acquisitions, Scheduled Earnings Releases, Appointments, Clinical Trials, and Stock Movements - Analyst Notes on Baxter, AcelRx, Synta Pharmaceuticals, Spectranetics, and NuVasive
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Baxter International Inc. (NYSE: BAX), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), The Spectranetics Corporation (NASDAQ: SPNC), and NuVasive, Inc. (NASDAQ: NUVA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Synta Announces Presentations at the 2014 Annual Meeting of the American Association of Cancer Research
Business Wire - Mon Apr 07, 6:30AM CDT
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that poster presentations related to studies with ganetespib, a selective Hsp90 inhibitor in clinical development by the company, and the company's Hsp90 inhibitor drug conjugates (HDC) will be presented at the 2014 Annual Meeting of the American Association of Cancer Research in San Diego, California. Poster presentations include:
Candidate Selection for Clinical Trials, Financial Results, and Patient Enrollments for Phase I Study - Analyst Notes on Synta, Ziopharm, Aastrom, Agios, and OncoMed
PR Newswire - Tue Mar 25, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Synta Pharmaceuticals Corp. (NASDAQ: SNTA), ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), Aastrom Biosciences, Inc. (NASDAQ: ASTM), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), and OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
This Week in Biotech: Endocyte Doubles, Intercept Wobbles, and Geron Gets Smacked Again
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 22, 12:45PM CDT
With the SPDR S&P Biotech Index up 57% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Synta Pharmaceuticals Corp. (SNTA) Catches Eye: Stock Jumps 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 7:44AM CDT
Synta Pharmaceuticals Corp. was a big mover last session, as the company saw its shares rise 9.5% on the day.
Why Synta Pharmaceuticals, Herman Miller, and Tower Semiconductor Jumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Thu Mar 20, 7:00PM CDT
After yesterday's surprise comments from Fed Chair Janet Yellen regarding the potential for interest rate hikes by next year, many investors weren't sure how stocks would react the morning after. But encouraging economic news from a rise in the...
Guess and Lennar are big market movers
AP - Thu Mar 20, 4:29PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
5 Stocks Under $10 Set to Soar
at The Street - Thu May 08, 12:57PM CDT
These under-$10 stocks look poised to trade higher from current levels.
Rectal Cancer - Pipeline Review, H1 2014
M2 - Thu May 08, 6:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d94ppq/rectal_cancer) has announced the addition of the "Rectal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Rectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rectal Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Rectal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Rectal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Rectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Rectal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - AbbVie Inc. - Celltrion, Inc. - Eisai Co., Ltd. - GenVec, Inc. - GlaxoSmithKline plc - Hanwha Chemical Corporation - Isofol Medical AB - Merck & Co., Inc. - Merck KGaA - Nanobiotix - Peregrine Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. For more information visit http://www.researchandmarkets.com/research/d9...tal_cancer
Synta Reports First Quarter 2014 Financial Results and Provides Corporate Update
Business Wire - Thu May 08, 6:01AM CDT
--Ganetespib Included in Six Large, Randomized Clinical Trials
Synta Announces Results From Final Analysis of the GALAXY-1 Trial of Ganetespib in NSCLC
Business Wire - Thu May 08, 6:01AM CDT
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced final results from the GALAXY-1 trial, a global, randomized, multi-center study designed to identify the patients with advanced non-small cell lung cancer (NSCLC) with adenocarcinoma histology most likely to benefit from second-line treatment with the Company's lead drug candidate, the Hsp90 inhibitor ganetespib, in combination with docetaxel versus docetaxel alone. Ganetespib is a next-generation inhibitor of the chaperone protein Hsp90, which is critical for the activation and stability of numerous proteins that drive cancer growth and proliferation. Ganetespib has been studied in over 1000 patients to date.
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/grpwf5/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Involved: - ATLAB Pharma SAS - AbbVie Inc. - Active Biotech AB - Astellas Pharma Inc. - AstraZeneca PLC - Bavarian Nordic A/S - Bellicum Pharmaceuticals, Inc. - Bind Therapeutics, Inc. - Bostwick Laboratories, Inc. - CellCentric Ltd. - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - Exelixis, Inc. - GTx, Inc. - GenSpera, Inc. - Genentech, Inc. - Medivation, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Novartis AG - Oncolytics Biotech Inc. - Oncothyreon Inc. - Onyx Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Sotio a.s. - Supratek Pharma Inc. - Synta Pharmaceuticals Corp. Drug Profiles: - enzalutamide - orteronel - custirsen sodium - tasquinimod - enzalutamide - cabozantinib (s)-malate - Prostvac - DCVAC/PCa - patupilone - DI-17-E-6 - olaratumab - navitoclax - vandetanib - PSMA ADC - GTx-758 - linsitinib - olaparib - panobinostat - carfilzomib - ganetespib - pelareorep - PX-866 - CV-9103 - G-202 - docetaxel targeted nanoparticles - buparlisib hydrochloride - NLG-8189 - Adenovirus/PSA Vaccine - TL-118 - CV-9104 For more information visit http://www.researchandmarkets.com/research/grpwf5/metastatic
Fallopian Tube Cancer - Pipeline Review, H1 2014: 30 Companies and 37 Drugs Profiled
M2 - Wed May 07, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7chq8b/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AbbVie Inc. - Acceleron Pharma, Inc. - Amgen Inc. - Boehringer Ingelheim GmbH - California Stem Cell, Inc. - Cell Therapeutics, Inc. - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Daiichi Sankyo Company, Limited - EGEN, Inc. - Eli Lilly and Company - GlaxoSmithKline plc - ImmunoGen, Inc. - Immunovaccine, Inc. - Incyte Corporation - Lee's Pharmaceutical Holdings Limited - MEI Pharma, Inc. - MabVax Therapeutics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OncoMed Pharmaceuticals, Inc. - Oncolytics Biotech Inc. - Oxford BioMedica plc - Pharma Mar, S.A. - Pharmacyclics, Inc. - Recepta Biopharma S.A. - Spectrum Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - TRION Pharma GmbH Drug Profiles: - pazopanib hydrochloride - trebananib - paclitaxel poliglumex - paclitaxel - MEK-162 - idronoxil - trabectedin - alisertib - dalantercept - elesclomol - TroVax - ramucirumab - pelareorep - nintedanib - catumaxomab - CRLX-101 - VTX-2337 - gimatecan - exatecan mesylate - RebmAb-100 - EGEN-001 - NSC-748933 - INCB-24360 - birinapant - rucaparib - metformin - Cancer Stem Cell Therapy - DPX-Survivac - ganetespib - pralatrexate For more information visit http://www.researchandmarkets.com/research/7c...opian_tube
Synta to Host Conference Call and Webcast of First Quarter 2014 Financial Results on May 8, 2013
Business Wire - Tue Apr 29, 4:00PM CDT
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that it will report its first quarter 2014 financial results on Thursday, May 8, 2014, before market open.
Global Gastrointestinal Stromal Tumor (GIST) Therapeutics Pipeline Review 2014 - Analysis of 16 Companies & 23 Drug Profiles
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8rx8bp/gastrointestinal) has announced the addition of the "Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumor (GIST) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Gastrointestinal Stromal Tumor (GIST) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Gastrointestinal Stromal Tumor (GIST) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Eli Lilly and Company - Novartis AG - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Bayer AG - Ariad Pharmaceuticals, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chipscreen Biosciences Ltd - Ambit Biosciences Corporation - Deciphera Pharmaceuticals, LLC - Xcovery, Inc. - AB Science - Clovis Oncology, Inc. - EirGen Pharma Ltd. - AROG Pharmaceuticals LLC Drug Profiles - regorafenib - masitinib - nilotinib - masitinib - olaratumab - linsitinib - ponatinib - AT-13387 - ganetespib - dovitinib lactate - crenolanib - luminespib - MEK-162 - TH-302 - buparlisib hydrochloride - CS-2164 - Mixed Bacterial Vaccine - X-82 - quizartinib - DCC-2618 - Mutant cKIT Inhibitor - Drug Targeting c-Kit - Eir-108 For more information visit http://www.researchandmarkets.com/research/8r...intestinal
Global Polycystic Kidney Disease Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8fdfv7/polycystic_kidney) has announced the addition of the "Global Polycystic Kidney Disease Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Polycystic Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Kidney Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Emergent BioSolutions Inc. - Plexxikon Inc. - Pfizer Inc. - Synta Pharmaceuticals Corp. - Metabolic Solutions Development Co. - IC-MedTech, Inc. - Endocyte, Inc. - ManRos Therapeutics - DiscoveryBiomed, Inc. - Otsuka Holdings Co., Ltd. - Kadmon Pharmaceuticals, LLC Drug Profiles - tolvaptan - tolvaptan - lanreotide acetate - bosutinib - KD-020 - KD-019 - GLG-302 - MSDC-0160 - MSDC-0602 - TNFR x TWEAKR - EC-0371 - Polycystic Kidney Disease Program - Small Molecule to Inhibit Raf Kinase for Polycystic Kidney Disease - STA-2842 - RCMC-30 - Small Moleucles to Activate AMPK for Polycystic Kidney Disease - Drug For Polycstic Kidney Disease - Drugs Targeting CIL-1 for Genetic Disorders and Polycystic Kidney Disease - Drugs for Polycystic Kidney Disease - Small Molecules to Activate Somatostatin Receptor Type 4 for Oncology, Genito Urinary System And Sex Hormones and Metabolic Disorders - (Vitamin C Vitamin K3) For more information visit http://www.researchandmarkets.com/research/8f...tic_kidney
Global Peritoneal Cancer Therapeutics Pipeline Review 2014 - Analysis of 32 Companies & 37 Drug Profiles
M2 - Tue Apr 22, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kk76kx/peritoneal_cancer) has announced the addition of the "Peritoneal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peritoneal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peritoneal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peritoneal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Peritoneal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Boehringer Ingelheim GmbH - AstraZeneca PLC - GlaxoSmithKline plc - Bioniche Life Sciences, Inc. - Daiichi Sankyo Company, Limited - Oxford BioMedica plc - Millennium Pharmaceuticals, Inc. - Novartis AG - ImmunoGen, Inc. - Bayer AG - Incyte Corporation - Oncolytics Biotech Inc. - Pharmacyclics, Inc. - Synta Pharmaceuticals Corp. - Oasmia Pharmaceutical AB - MabVax Therapeutics, Inc. - Spectrum Pharmaceuticals, Inc. - Acceleron Pharma, Inc. - TRION Pharma GmbH - CerRx, Inc. - OncoMed Pharmaceuticals, Inc. - TetraLogic Pharmaceuticals - Innate Therapeutics Limited - CritiTech, Inc. - Pharma Mar, S.A. - VentiRx Pharmaceuticals, Inc. - Genelux Corporation - Clovis Oncology, Inc. - California Stem Cell, Inc. - EGEN, Inc. Drug Profiles - Cancer Stem Cell Therapy - DPX-Survivac - EGEN-001 - GL-ONC-1 - Globo-H-GM2-sTn-TF-Tn-KLH Vaccine - IMGN-853 - IMT-1012 - INCB-24360 - MEK-162 - MIS-416 - MV-NIS Vaccine - Mycobacterial Cell Wall-DNA Complex Program - NSC-748933 - OC-DC Vaccine - Theranean - TroVax - VTX-2337 - abexinostat hydrochloride - alisertib - birinapant - catumaxomab - dalantercept - demcizumab - elesclomol - exatecan mesylate - fenretinide - ganetespib - metformin - nintedanib For more information visit http://www.researchandmarkets.com/research/kk...eal_cancer
Global Metastatic Pancreatic Cancer Therapeutics Pipeline Review 2014 - Analysis of 27 Companies & 37 Drug Profiles
M2 - Tue Apr 22, 3:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gctlqw/metastatic) has announced the addition of the "Metastatic Pancreatic Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Pancreatic Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Pancreatic Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Metastatic Pancreatic Cancer - Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Adherex Technologies Inc. - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - FibroGen, Inc. - Novartis AG - Pfizer Inc. - Celgene Corporation - Bayer AG - Halozyme Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - Immunomedics, Inc. - Synta Pharmaceuticals Corp. - NanoCarrier Co., Ltd. - Rexahn Pharmaceuticals, Inc. - Insys Therapeutics, Inc. - OncoMed Pharmaceuticals, Inc. - Merrimack Pharmaceuticals, Inc. - Pharma Mar, S.A. - AB Science - Oncovir, Inc. - ParinGenix, Inc. - Regulon Inc. - Fountain Biopharma Inc. - Oncozyme Pharma Inc. - AbbVie Inc. Drug Profiles - paclitaxel albumin-bound - irinotecan sucrosofate liposomal - masitinib - cisplatin liposomal - cisplatin - refametinib - selumetinib sulfate - trametinib dimethyl sulfoxide - docetaxel - paclitaxel albumin-bound - ganetespib - RX-0201 - irinotecan sucrosofate liposomal - PGX-100 - lurbinectedin - yttrium Y 90 clivatuzumab tetraxetan - Cancer Inhibitor Macrobeads - TL-118 - LY-2090314 - hydroxychloroquine - LY-2495655 - PEGPH-20 - M-402 - pentamidine isethionate - veliparib - galunisertib - ADH-1 - FG-3019 - demcizumab - LCL-161 For more information visit http://www.researchandmarkets.com/research/gctlqw/metastatic
5 Stocks Insiders Love Right Now
at The Street - Wed Apr 16, 12:06PM CDT
Insiders at these companies are scooping up shares of their own stock lately.
Synta Pharmaceuticals Enters Into Agreement to Sell $5.0 Million in Common Stock Directly to an Affiliate of Synta Board Member Bruce Kovner
Business Wire - Mon Apr 14, 7:02AM CDT
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the entry into a Subscription Agreement with an entity affiliated with Bruce Kovner, one of Synta's directors and its largest stockholder, to sell 1,250,000 shares of its common stock at a price of $4.01 per share. The proceeds to Synta are expected to be approximately $5.0 million after deducting estimated offering expenses payable by Synta. The shares were offered directly without a placement agent, underwriter, broker or dealer.
Acquisitions, Scheduled Earnings Releases, Appointments, Clinical Trials, and Stock Movements - Analyst Notes on Baxter, AcelRx, Synta Pharmaceuticals, Spectranetics, and NuVasive
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Baxter International Inc. (NYSE: BAX), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), The Spectranetics Corporation (NASDAQ: SPNC), and NuVasive, Inc. (NASDAQ: NUVA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Synta Announces Presentations at the 2014 Annual Meeting of the American Association of Cancer Research
Business Wire - Mon Apr 07, 6:30AM CDT
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that poster presentations related to studies with ganetespib, a selective Hsp90 inhibitor in clinical development by the company, and the company's Hsp90 inhibitor drug conjugates (HDC) will be presented at the 2014 Annual Meeting of the American Association of Cancer Research in San Diego, California. Poster presentations include:
Candidate Selection for Clinical Trials, Financial Results, and Patient Enrollments for Phase I Study - Analyst Notes on Synta, Ziopharm, Aastrom, Agios, and OncoMed
PR Newswire - Tue Mar 25, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Synta Pharmaceuticals Corp. (NASDAQ: SNTA), ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), Aastrom Biosciences, Inc. (NASDAQ: ASTM), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), and OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
This Week in Biotech: Endocyte Doubles, Intercept Wobbles, and Geron Gets Smacked Again
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 22, 12:45PM CDT
With the SPDR S&P Biotech Index up 57% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Synta Pharmaceuticals Corp. (SNTA) Catches Eye: Stock Jumps 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 7:44AM CDT
Synta Pharmaceuticals Corp. was a big mover last session, as the company saw its shares rise 9.5% on the day.
Why Synta Pharmaceuticals, Herman Miller, and Tower Semiconductor Jumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Thu Mar 20, 7:00PM CDT
After yesterday's surprise comments from Fed Chair Janet Yellen regarding the potential for interest rate hikes by next year, many investors weren't sure how stocks would react the morning after. But encouraging economic news from a rise in the...
Guess and Lennar are big market movers
AP - Thu Mar 20, 4:29PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
